AKT1 and hemangioma: Low-concentration rapamycin has also demonstrated efficacy in inhibiting hemangioma endothelial cell proliferation and migration both in vitro and in vivo by reducing the activation of the protein kinase B/mTOR/S6 signaling pathway [65].